All the news Showing 8 of 28 articles from: Pan-genotypic regimensGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources AbbVie pangenotypic combination cures 98% or above across genotypes Keith Alcorn / 16 November 2016 AbbVie’s combination of glecaprevir and pibrentasvir cured at least 98% of people with hepatitis C in three large clinical trials covering five out of six genotypes of the virus, and is ... AbbVie pangenotypic combination cures almost all hard-to-treat people with HCV genotype 3 Keith Alcorn / 16 November 2016 AbbVie’s pangenotypic combination of glecaprevir and pibrentasvir cured almost all of the hardest-to-treat genotype 3 patients – those with cirrhosis and/or previous treatment experience – in a phase II trial, and looks suitable ... US regulators approve Gilead's Epclusa combo pill for all hepatitis C genotypes Liz Highleyman / 04 July 2016 On June 28 the US Food and Drug Administration approved Gilead Sciences Epclusa, a new once-daily combination pill containing sofosbuvir and velpatasvir, for the treatment of adults with hepatitis C virus (HCV) genotypes ... FDA Approves Gilead's Epclusa Combo Pill for All Hepatitis C Genotypes HIVandHepatitis.com / 04 July 2016 ABT-493 + ABT-530 cures most hepatitis C patients across genotypes in SURVEYOR studies Liz Highleyman / 03 June 2016 A co-formulation of AbbVie's experimental next-generation direct-acting antiviral agents ABT-493 and ABT-530 was well-tolerated and led to sustained virological response in 97% or more of patients across all hepatitis C virus (HCV) genotypes ... Washington Ordered to Cover Hepatitis C Drugs During Lawsuit Bloomberg / 31 May 2016 AbbVie pan-genotypic combination for hepatitis C achieves 97-100% cure rate in genotype 3 Keith Alcorn / 20 April 2016 A new combination of direct-acting antivirals developed by AbbVie is highly effective in curing hepatitis C in people with genotype 3 infection and cirrhosis, results of two phase II studies presented at last ... Ravidasvir plus sofosbuvir demonstrates high cure rate for people with hepatitis C genotype 4 Liz Highleyman / 02 March 2016 Sofosbuvir plus the investigational HCV NS5A inhibitor ravidasvir, with or without ribavirin, cured 95 to 100% of people with hepatitis C virus (HCV) genotype 4, the most common type in Egypt, ... ← Prev123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive